Rein Therapeutics Total Liabilities 2017-2024 | RNTX

Rein Therapeutics total liabilities from 2017 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Rein Therapeutics Total Liabilities 2017-2024 | RNTX

Rein Therapeutics total liabilities from 2017 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$147B
Gilead Sciences (GILD)$116B
Bristol Myers Squibb (BMY)$115.8B
Vertex Pharmaceuticals (VRTX)$110.2B
CSL (CSLLY)$81.9B
Regeneron Pharmaceuticals (REGN)$74.7B
GSK (GSK)$69.3B
Argenex SE (ARGX)$38.6B
Alnylam Pharmaceuticals (ALNY)$34.4B
BioNTech SE (BNTX)$27.6B
Illumina (ILMN)$22.3B
BeiGene (ONC)$21.7B
Biogen (BIIB)$20.8B
Moderna (MRNA)$14.8B
Insmed (INSM)$14B
Incyte (INCY)$13.9B
Genmab (GMAB)$13.9B
Genmab (GNMSF)$13.9B
Intra-Cellular Therapies (ITCI)$13.5B
Bio-Techne Corp (TECH)$12.5B
BioMarin Pharmaceutical (BMRN)$11.8B
Sarepta Therapeutics (SRPT)$11.1B
Vaxcyte (PCVX)$10.8B
QIAGEN (QGEN)$10.8B
Exact Sciences (EXAS)$10.1B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Bio-Rad Laboratories (BIO.B)$9.8B
Exelixis (EXEL)$9.4B
Repligen (RGEN)$9.3B
Roivant Sciences (ROIV)$8.1B